In vivo evaluation is the cornerstone of radiopharmaceutical preclinical development, bridging the gap between cellular-level insights and clinical translation by characterizing biodistribution, pharmacokinetics, therapeutic efficacy, and safety profiles in living animal systems. Protheragen delivers a comprehensive suite of in vivo services tailored to radiopharmaceutical programs—from quantitative biodistribution and dosimetry through multi-species PK/ADME studies, real-time imaging, and GLP-compliant toxicity assessment—enabling data-driven decision-making at every stage of your development pipeline.
In vivo radiopharmaceutical evaluation encompasses a systematic array of animal-based studies designed to characterize the behavior of radiolabeled compounds within a living organism, providing critical data on biodistribution, pharmacokinetics, therapeutic efficacy, and toxicological safety that cannot be fully replicated by in vitro methods. These studies typically employ tumor-bearing xenograft, orthotopic, or patient-derived xenograft (PDX) models to assess how a radiopharmaceutical distributes between target and non-target tissues, how rapidly it clears from the circulation, and whether it achieves therapeutically relevant radiation doses in tumors while sparing dose-limiting organs such as the kidneys, bone marrow, and salivary glands.
Fig 1. Radiopharmaceutical-drug screen for in vivo cytotoxic effect size using zebrafish. (Kunos, Charles A., et al., 2021)
Biodistribution studies are conducted by administering the radiopharmaceutical to animals and subsequently measuring radioactivity in excised tissues at multiple time points, with results expressed as percentage injected dose per gram (%ID/g) or standardized uptake value (SUV), while dynamic micro-PET, micro-SPECT, or micro-CT imaging enables longitudinal, non-invasive visualization of pharmacokinetic processes.
The in vivo radiopharmaceutical evaluation landscape is rapidly evolving, driven by the clinical expansion of targeted radionuclide therapy (TRT), the theranostic paradigm, and the demand for more predictive, translationally relevant preclinical models. Traditional subcutaneous xenografts are increasingly complemented by orthotopic implants and patient-derived xenografts (PDX) that better recapitulate tumor microenvironment physiology, vascular architecture, and stromal interactions. Concurrently, the shift from beta-emitting to alpha-emitting radionuclides has introduced new preclinical complexities, necessitating surrogate diagnostic imaging and advanced dosimetry methods. The table below summarizes key technological and methodological advancements shaping modern in vivo radiopharmaceutical development.
| Advancement | Key Methodology | Advantages |
|---|---|---|
| Voxel-Level Dosimetry | Monte Carlo simulation on PET/CT images; GATE-based 3D dose distribution mapping; dose-volume histograms (DVHs) | Patient-specific heterogeneous tissue composition; direct tumor absorbed dose estimation; overcomes phantom-based MIRD limitations |
| Orthotopic Tumor Models | Tumor cells implanted into anatomically correct site; monitored by BLI, MRI, or CT; higher vascular density than s.c. models | Better mimics clinical tumor physiology and drug accessibility; improved translational relevance for dosimetry to adjacent organs |
| Patient-Derived Xenografts (PDX) | Patient tumor biopsies engrafted into immunodeficient mice; serial passaging; retain human stromal components and heterogeneity | Higher predictive value for clinical outcomes; preserves treatment history and resistance patterns; enables personalized screening |
| Micro-PET/SPECT/CT Imaging | Dynamic small-animal PET/SPECT with CT co-registration; quantitative SUV and %ID/g; time-activity curves for compartmental modeling | Non-invasive longitudinal monitoring; reduces inter-animal variability; enables pharmacokinetic modeling (AUC, clearance, Vd) |
| Surrogate Diagnostic Imaging for TAT | Theranostic pairing: diagnostic isotope (e.g., 111In, 68Ga) for imaging; therapeutic isotope (e.g., 225Ac) for therapy; assumes matched biodistribution | Enables preclinical imaging of alpha-emitters; supports patient-specific treatment planning; bridges diagnostic and therapeutic data |
| Fractionated Dosing Regimens | Total radioactivity divided into multiple injections (e.g., 2x or 3x/week); evaluated for tumor growth inhibition and toxicity | Better tolerated than single high doses; reduced dose-limiting organ toxicity; enables higher cumulative tumor dose |
| Bioluminescence Imaging (BLI) | Luciferase-expressing tumor cells; non-invasive longitudinal tumor burden quantification; validated by caliper and histology | Real-time monitoring of tumor growth and response; reduces animal numbers through repeated measures; high sensitivity for early detection |
| Multi-Species PK/ADME | Rodents to rabbits and non-human primates; various administration routes (IV, IM, SC, IP, oral, nasal, transdermal) | Robust and translatable data for human studies; identifies species-specific differences in metabolism and clearance |
| Radiation Safety & ALARA Compliance | Personnel dosimetry (whole body, ring, finger badges); environmental monitoring; shielding design; waste management; bioassay programs | Protects staff, patients, and environment; ensures regulatory compliance (NRC, IAEA, EMA); minimizes occupational exposure |
| Toxicokinetic (TK) Integration | Serial blood sampling during repeat-dose toxicology; measurement of total and intact radiopharmaceutical; correlation with toxicity | Closes loop between dose, exposure, and toxicity; enables safety margin calculations; supports FIH dose justification |
Protheragen delivers a comprehensive portfolio of in vivo radiopharmaceutical services designed to generate robust, quantitative data at every stage of preclinical development. From quantitative biodistribution and voxel-level dosimetry through multi-species PK/ADME studies, real-time micro-PET/SPECT/CT imaging, and GLP-compliant toxicity assessment, our integrated platform provides the pharmacological, pharmacokinetic, and safety insights needed to de-risk your program before advancing to clinical trials. Our facilities are constructed with reference to GLP standards and qualified for the manipulation of a broad spectrum of diagnostic and therapeutic radionuclides, with a diverse animal model portfolio spanning mice, rats, guinea pigs, rabbits, dogs, pigs, and monkeys.
We perform multi-time-point biodistribution tests on CDX/PDX orthotopic tumor models to measure radioactivity in tumor and major organs, calculating tumor-organ ratios. We conduct organ-level MIRD and voxel Monte Carlo dosimetry from micro-PET/CT to output absorbed dose and DVH data.
We assess anti-tumor efficacy across subcutaneous, orthotopic and PDX models via TGI, survival and imaging readouts, grading tumor response as CR/PR/SD/PD. We test combination therapies and fractionated dosing to boost tumor suppression and improve safety tolerance.
We run cross-species PK studies covering multiple administration routes, collect serial blood samples to compute core PK parameters. Combined with in vitro ADME data, we identify compound drawbacks and optimize clinical dosing schemes early.
Equipped with micro-PET/SPECT/CT, we carry out non-invasive dynamic imaging to draw TAC curves and complete compartmental kinetic analysis. Co-registered CT supports ROI quantification for both diagnostic and therapeutic radionuclide tracers.
We build CDX, PDX and orthotopic tumor models with distinct translational strengths, monitor tumor burden via BLI/MRI/CT. All models undergo IHC and genomic target validation for customized efficacy and biodistribution research.
We measure renal and hepatobiliary excretion by collecting urine and feces, test nephroprotective interventions for kidney-targeted tracers. We design radioactive waste workflows complying with ALARA and official emission control standards.
We deliver GLP-standard acute and repeated-dose toxicology following ICH S9 and 21 CFR Part 58. We tailor study protocols based on tracer mass and radionuclide properties, pairing toxicokinetic detection with full hematology and histopathology analysis.
We track radiation-caused bone marrow damage through blood routine, marrow histopathology and single-cell sequencing. We differentiate reversible and irreversible myelotoxicity by long-term recovery curves to set safe split-dosing limits.
We detect renal injury via serum biomarkers and kidney radioactivity quantification, test kidney-protective reagents for peptide radiopharmaceuticals. We perform full renal histopathology to diagnose radiation nephropathy and optimize protective co-administration plans.
We implement full radiation safety management including staff personal dosimetry, facility shielding and regular environmental monitoring. Complete ALARA records and inspection files are preserved to meet NRC, IAEA and local regulatory audit demands.
Our in vivo evaluation workflow follows a structured, tiered approach that progressively characterizes radiopharmaceutical behavior from initial biodistribution through advanced therapeutic and toxicological assessment. Each tier generates quantitative data that informs downstream clinical study design and regulatory strategy, ensuring that only compounds with robust in vivo profiles advance to human trials.
Ready to accelerate your radiopharmaceutical program with comprehensive in vivo evaluation? Contact us today to discuss your biodistribution, dosimetry, tumor targeting, PK/ADME, imaging, or toxicity assessment requirements. Our team is prepared to reach out to you with a tailored in vivo study design that aligns with your target, radionuclide, and regulatory pathway. Let Protheragen provide the quantitative, mechanistic data foundation your program needs to advance confidently into clinical development.
Reference